MIAMI BEACH, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AirSculpt® Technologies, Inc., (“AirSculpt”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced the opening of centers in Austin, Texas and Orange County, California. The new openings increases the company’s center count to 24 locations throughout the United States and Canada.
AirSculpt® is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at Elite Body Sculpture offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
“We’re delighted to deliver our premium AirSculpt® experience to the Austin and Orange County markets,” said Todd Magazine, Chief Executive Officer at AirSculpt® Technologies. “The opening of our third Texas and third Southern California locations speaks to the growing demand for our patented AirSculpt technology.”
The Austin center is easily accessible in Bridge Point Square at 6200 Bridgepoint Parkway, Building IV, Suite 150, Austin, TX 78730, (737) 484 9625.
The Orange County center, which opens March 31st, is conveniently located 5 minutes from the John Wayne Airport. The address is: 17877 Von Karman Ave, Suite 350, Irvine, CA 92614, (949) 404 4440.
More than 40,000 AirSculpt cases have been performed in Elite Body Sculpture’s premium locations throughout the U.S and Canada. For additional information about scheduling a virtual or in-person consultation at any of the 24 centers, visit elitebodysculpture.com.
About AirSculpt®
AirSculpt® Technologies (NASDAQ: AIRS) is an experienced, fast-growing national provider of body contouring procedures delivering a premium consumer experience under its brand, Elite Body Sculpture. At Elite Body Sculpture, we provide custom body contouring using our proprietary AirSculpt® method that removes unwanted fat in a minimally invasive procedure, producing dramatic results. It is our mission to generate the best results for our patients.
Investor Contact:
Steven Halper/Caroline Paul
Managing Directors, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Stephanie Evans Greene
Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.70 |
Daily Change: | 0.11 6.92 |
Daily Volume: | 117,572 |
Market Cap: | US$98.400M |
December 17, 2024 November 08, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load